[go: up one dir, main page]

DE59407414D1 - Use of leflunomide to inhibit tumor necrosis factor alpha - Google Patents

Use of leflunomide to inhibit tumor necrosis factor alpha

Info

Publication number
DE59407414D1
DE59407414D1 DE59407414T DE59407414T DE59407414D1 DE 59407414 D1 DE59407414 D1 DE 59407414D1 DE 59407414 T DE59407414 T DE 59407414T DE 59407414 T DE59407414 T DE 59407414T DE 59407414 D1 DE59407414 D1 DE 59407414D1
Authority
DE
Germany
Prior art keywords
necrosis factor
factor alpha
leflunomide
tumor necrosis
inhibit tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59407414T
Other languages
German (de)
Inventor
Klaus Ulrich Dr Weithmann
Robert Ryder Dr Bartlett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE59407414T priority Critical patent/DE59407414D1/en
Application granted granted Critical
Publication of DE59407414D1 publication Critical patent/DE59407414D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating diseases in which tumour necrosis factor alpha is involved. It is used as pharmaceutical.
DE59407414T 1993-01-08 1994-01-03 Use of leflunomide to inhibit tumor necrosis factor alpha Expired - Lifetime DE59407414D1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE59407414T DE59407414D1 (en) 1993-01-08 1994-01-03 Use of leflunomide to inhibit tumor necrosis factor alpha

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4300280 1993-01-08
DE59407414T DE59407414D1 (en) 1993-01-08 1994-01-03 Use of leflunomide to inhibit tumor necrosis factor alpha

Publications (1)

Publication Number Publication Date
DE59407414D1 true DE59407414D1 (en) 1999-01-21

Family

ID=6477855

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59407414T Expired - Lifetime DE59407414D1 (en) 1993-01-08 1994-01-03 Use of leflunomide to inhibit tumor necrosis factor alpha

Country Status (8)

Country Link
US (1) US5547970A (en)
EP (1) EP0607776B1 (en)
JP (1) JPH06234637A (en)
AT (1) ATE174219T1 (en)
DE (1) DE59407414D1 (en)
DK (1) DK0607776T3 (en)
ES (1) ES2124801T3 (en)
GR (1) GR3029490T3 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1997042820A1 (en) 1996-05-16 1997-11-20 Duke University Tristetraprolin
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19702988A1 (en) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazole and crotonic acid amide derivatives and their use as pharmaceuticals and diagnostics
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
ES2166205T3 (en) * 1997-08-08 2002-04-01 Aventis Pharma Gmbh CRYSTAL FORM OF ACID AMIDA N- (4-TRIFLUOROMETILFENIL) -5-METHYLISOXAZOL-4-CARBOXYL.
DE69937904T2 (en) * 1998-03-11 2009-01-02 James W. Oak Park Williams ANTIVIRAL USES OF LEFLUNOMID PRODUCTS
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
SG2011076551A (en) 2001-06-26 2015-08-28 Amgen Inc Antibodies to opgl
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
WO2006001961A2 (en) * 2004-05-21 2006-01-05 The Uab Research Foundation Compositions and methods relating to pyrimidine synthesis inhibitors
KR101351181B1 (en) 2010-05-11 2014-01-14 가천대학교 산학협력단 Method for inhibiting cell death induction by inhibiting synthesis or secretion of AGE-albumin in mononuclear phagocyte system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (en) * 1978-12-16 1980-07-03 Hoechst Ag AN ISOXAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AGENT AND USE THEREOF
DE3534440A1 (en) * 1985-09-27 1987-04-02 Hoechst Ag DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES
RU2084223C1 (en) * 1990-05-18 1997-07-20 Хехст АГ Use of isoxazole-4-carboxylic acid amides and hydroxyalkylidenecyanoacetic acid amides
ATE197646T1 (en) * 1990-08-06 2000-12-15 Chiron Corp METHOD FOR DETECTING CYTOKINE CONVERTASE INHIBITORS

Also Published As

Publication number Publication date
EP0607776B1 (en) 1998-12-09
US5547970A (en) 1996-08-20
EP0607776A2 (en) 1994-07-27
ATE174219T1 (en) 1998-12-15
JPH06234637A (en) 1994-08-23
GR3029490T3 (en) 1999-05-28
DK0607776T3 (en) 1999-08-16
EP0607776A3 (en) 1994-08-31
ES2124801T3 (en) 1999-02-16

Similar Documents

Publication Publication Date Title
DE59407414D1 (en) Use of leflunomide to inhibit tumor necrosis factor alpha
ATE174218T1 (en) USE OF LEFLUNOMIDE TO INHIBIT INTERLEUKIN 1 BETA
DK130387A (en) TRANSGLUTAMINASE INHIBITORS
EP0735870A4 (en) USE OF PHOSPHOLIPASE-A2 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
DE69727695D1 (en) USE OF MATRIX METALLOPROTEINASE INHIBITORS TO PROMOTE Wound Healing
DE69634900D1 (en) PROTEINTYROSINE KINASEINHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS
DE69733834D1 (en) THYROXINE ANALOGS WITH NO SIGNIFICANT HORMONAL ACTIVITY FOR THE TREATMENT OF MALICIOUS TUMORS
ATE222489T1 (en) THYROXINE ANALOGUE WITHOUT SIGNIFICANT HORMONAL EFFECT FOR THE TREATMENT OF MALIGNANT TUMORS
ATE258796T1 (en) USE OF VITAMIN D4 DERIVATIVES TO TREAT SKIN DISEASES
ATE120372T1 (en) ANTIBODIES FOR ANTILYMPHOCYTE ANTIBODIES THERAPY.
ATE174220T1 (en) USE OF LEFLUNOMIDE TO INHIBIT INTERLEUKIN 8
EA200001124A1 (en) METHOD OF GENE THERAPY
ATE124681T1 (en) MEDICINAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS.
DE59902666D1 (en) EDELFOSIN FOR TREATING BRAIN TUMORS
DE3861494D1 (en) PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT.
ATE174217T1 (en) USE OF LEFLUNOMIDE TO INHIBIT INTERLEUKIN 1 ALPHA
DE3686688D1 (en) USE OF SULFANILAMIDO QUINOXALINES FOR TREATING NEOPLASTIC DISEASES.
DE59302465D1 (en) USE OF BARRELS FOR THE THERAPY OR PROPHYLAXIS OF BLOOD DISEASES
ATE229343T1 (en) COMBINATION OF TEMOZOLOMIDE AND ALPHA INTERFERON FOR THE TREATMENT OF ADVANCED CANCER
DE3684825D1 (en) USE OF N- (1-ALLYL-2-PYRROLIDINYLMETHYL) -2-METHOXY-4-AMINO-5-METHYLSULFAMOYLBENZAMIDE FOR TREATING PARKINSON'S DISEASE.
DE69117566D1 (en) Use of isomonools for the treatment and prophylaxis of cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition